Clinical trials: Gastric Cancer, completed
Cancer of Stomach, Cancer of the Esophagus
Nordic Gastric and Esophageal Tumor Study
This is a population-based case-control study in all 5 Nordic countries from 1994 onwards. Cases with esophageal or gastric cancer will be compared with 10 times as many population controls.
- Conditions
- Cancer of Stomach, Cancer of the Esophagus, Drug Use
- Trial name
- NordGETS (NCT05688761)
- Testing
- Proton pump inhibitor
- Where
- Sweden
- Volunteers
- 900,000 people
- Sponsor
- Karolinska Institutet
Gastric Cancer
Neo-Sequence 1: Neoadjuvant Chemotherapy With or Without Antiangiogenesis and Sequential Immunotherapy for HER2-negative MMR-proficient Locally Advanced Gastric or Gastroesophageal Adenocarcinoma
This is a single-institution, prospective phase II trial designed to evaluate the efficacy of neoadjuvant chemotherapy and sequential immunotherapy in patients with locally advanced esophagogastric junction and gastric…
- Trial name
- NCT05540145
- Testing
- SOX plus Paclitaxel with or without antiangiogenesis followed by PD-1 antibody
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Gastric Cancer
Study of ARQ 197 Monotherapy
A phase II open-label study with ARQ 197 administered orally and twice daily as monotherapy in patients with previously treated advanced/recurrent gastric cancer.
- Trial name
- ARQ 197-004 (NCT01152645)
- Testing
- ARQ 197
- Where
- 2 sites in Japan, South Korea
- Volunteers
- 31 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Colorectal Cancer With Hepatic Metastases, Pancreas Cancer With Hepatic Metastase
TKM 080301 for Primary or Secondary Liver Cancer
Background: Cancer in the liver can start in the liver (e.g., primary liver cancer or hepatocellular cancer) or spread to the liver from cancers in other parts of the body (e.g.
- Conditions
- Colorectal Cancer With Hepatic Metastases, Pancreas Cancer With Hepatic Metastase, Gastric Cancer With Hepatic Metastase, Breast Cancer With Hepatic Metastase
- Trial name
- NCT01437007
- Testing
- TKM-080301
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Gastric Cancer
Clinical Trials for the Prevention of Gallstone Formation After Gastrectomy in Patient With Gastric Cancer
This study evaluates the efficacy and safety of DWJ1319 in the prevention of gallstone formation after gastrectomy in patient with gastric cancer.
- Trial name
- NCT02490111
- Testing
- DWJ1319
- Where
- 12 sites in South Korea
- Volunteers
- 521 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Stomach Neoplasms
Association Between Mitochondrial DNA Content and Risk of Gastric Cancer
Compelling epidemiological evidence indicates that alterations of mitochondrial DNA, including mutations and abnormal content of mitochondrial DNA (mtDNA), are associated with the initiation and development of gastric cancer.The…
- Trial name
- NCT02944539
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Air Force Military Medical University, China
Gastric Adenocarcinoma, Stage II Gastric Cancer
Irinotecan and Cisplatin in Treating Patients Who Are Undergoing Surgery For Locally Advanced Cancer of the Stomach or Gastroesophageal Junction
This phase II trial is studying how well giving irinotecan together with cisplatin works in treating patients who are undergoing surgical resection for locally advanced cancer of the stomach or gastroesophageal junction.
- Conditions
- Gastric Adenocarcinoma, Stage II Gastric Cancer, Stage III Gastric Cancer, Stage IV Gastric Cancer
- Trial name
- NCT00062374
- Testing
- Cisplatin, Computed Tomography, Fludeoxyglucose F-18
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Cancer, Solid Tumor
ACTolog in Patients With Solid Cancers
The study purpose is to learn about the safety and tolerability of IMA101 alone (Cohort 1) or in combination with atezolizumab (Cohort 2) in patients with advanced solid cancers that express pre-defined Immatics tumor targets.
- Trial name
- ACTolog (NCT02876510)
- Testing
- Fludarabine, Cyclophosphamide, IMA101 product
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Immatics US, Inc.
Squamous Cell Carcinoma of the Head and Neck, Melanoma
SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas
This is a Phase 1 first in human, open label, multi-center, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, anti-tumor activity and pharmacodynamic effects of SL-279252 in subjects with advanced…
- Conditions
- Squamous Cell Carcinoma of the Head and Neck, Melanoma, Non Small Cell Lung Cancer, Urothelial Carcinoma
- Trial name
- NCT03894618
- Testing
- SL-279252
- Where
- 5 sites in United States, Belgium and 2 more
- Volunteers
- 49 people
- Sponsor
- Shattuck Labs, Inc.
Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction
A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer
The main purpose of this study is to evaluate the safety and preliminary efficacy of the combination of the study drug known as ramucirumab plus pembrolizumab in participants with locally advanced and unresectable or metastatic…
- Conditions
- Gastric Adenocarcinoma, Adenocarcinoma of the Gastroesophageal Junction, Non-small Cell Lung Cancer, Carcinoma, Transitional Cell
- Trial name
- NCT02443324
- Testing
- Ramucirumab, Pembrolizumab
- Where
- 22 sites in United States, France and 4 more
- Volunteers
- 175 people
- Sponsor
- Eli Lilly and Company
Pancreatic Cancer, Lung Cancer
Perceptions of Exceptional Patients in Cancer Care Relating to Their Unusual Survival
The main objective of this study is to explore experiences and insights from exceptional patients, patients with cancer that were considered by their physicians as having exceptional course of survival related to their specific…
- Conditions
- Pancreatic Cancer, Lung Cancer, Stomach Cancer, Esophageal Cancer
- Trial name
- NCT02055313
- Volunteers
- 20 people
- Sponsor
- Meir Medical Center
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Trastuzumab Deruxtecan Plus Nivolumab Plus Capecitabine Plus Oxaliplatin for HER2 Low Gastric and Gastroesophageal Junction Adenocarcinoma
To evaluate the safety and tolerability of the combination therapy of T-DXd, nivolumab, and chemotherapy in patients with untreated HER2-low gastric or gastroesophageal junction adenocarcinoma, and to determine the recommended…
- Trial name
- T-DXd_HER2Low (NCT07529613)
- Testing
- T-DXd, Nivolumab, Capecitabine
- Where
- Japan
- Volunteers
- 30 people
- Sponsor
- National Cancer Center Hospital East
Gastric Cancer
Application of Serum Bile Acid Profile in the Diagnosis of Gastric Cancer
In this study, the composition and level of serum bile acids in patients with gastric cancer and non-gastric cancer were analyzed by detecting the serum bile acid profile, so as to develop new serological diagnostic methods for…
- Trial name
- NCT06031779
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Xijing Hospital of Digestive Diseases
Gastrointestinal Cancer
Validating M.D. Anderson Symptom Inventory (MDASI-GI) in GI Cancer Patients Under Chemotherapy
The goal of this study is to learn more about the symptoms that may occur in patients with GI cancer. The types of GI cancer being studied are cancers of the stomach, liver, pancreas, colon, and rectum.
- Trial name
- NCT00849979
- Testing
- Questionnaire, Interview
- Where
- United States
- Volunteers
- 184 people
- Sponsor
- M.D. Anderson Cancer Center
Early Gastric Cancer
Necessity Assessment of ME-NBI Targeted Biopsy Compared With EFB
The aim of the present study was to assess whether it was necessary to conduct magnifying endoscopy with narrow band imaging (ME-NBI) targeted biopsy compared with endoscopic forceps biopsy (EFB) from white light endoscopy in…
- Trial name
- NCT02738294
- Testing
- ME-NBI observation and ME-NBI targeted biopsy
- Where
- China
- Volunteers
- 211 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Cancer
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
RATIONALE: MS-275 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: This phase I trial is studying the side effects and best dose of MS-275 in treating patients with advanced solid…
- Trial name
- NCT00020579
- Testing
- entinostat
- Where
- 3 sites in United States
- Volunteers
- 75 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Lung Neoplasms, Esophageal Neoplasms
The Thoracic Peri-Operative Integrative Surgical Care Evaluation (POISE) Trial- Stage I
Stage I of the Thoracic-POISE study will pilot-test a broad-based, multi-agent integrative care intervention delivered by naturopathic doctors in conjunction with standard surgical and oncologic care of people with thoracic…
- Conditions
- Lung Neoplasms, Esophageal Neoplasms, Stomach Neoplasms
- Trial name
- POISE (NCT02845479)
- Testing
- Integrative Care
- Where
- 2 sites in Canada
- Volunteers
- 22 people
- Sponsor
- The Canadian College of Naturopathic Medicine
Lung Cancer, Gastric Cancer
Effect of Multi-Media Tool on Enrollment in Oncology Clinical Trials
The purpose of this research study is to test a touchscreen computer program, which allows patients to see information on a computer screen regarding cancer care, and specifically clinical trials.
- Conditions
- Lung Cancer, Gastric Cancer, Pancreatic Cancer
- Trial name
- NCT02020252
- Testing
- Testing an interactive technology in a diverse health literary population
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- University of Chicago
Gastric Cancer, Obesity
Compare the Oncological Benefit of Deep Neuromuscular Block in Gastric Cancer Obesity Patient
This study is designed to evaluate the impact of muscle relaxation during laparoscopic gastrectomy on oncological benefit, especially with obese patients over BMI 25.
- Trial name
- NCT03196791
- Testing
- Sugammadex Sodium
- Where
- South Korea
- Volunteers
- 196 people
- Sponsor
- Korea University Anam Hospital
Colorectal Cancer, Breast Cancer
Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors
SNB-101 is a novel nano-particle formulation of SN-38, the active metabolite of irinotecan(CPT-11). Study SNB101P01 is a multicenter, open-label, dose escalation, phase 1 study of SNB 101 with its active ingredient SN-38, in…
- Conditions
- Colorectal Cancer, Breast Cancer, Pancreas Cancer, Ovarian Cancer
- Trial name
- NCT04640480
- Testing
- SNB-101
- Where
- 3 sites in South Korea
- Volunteers
- 21 people
- Sponsor
- SN BioScience
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.